Grantham Mayo Van Otterloo & Co. LLC Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Grantham Mayo Van Otterloo & Co. LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 21.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 2,676,738 shares of the biopharmaceutical company’s stock after buying an additional 464,885 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Pfizer were worth $71,014,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Cullen Capital Management LLC increased its stake in Pfizer by 12.9% in the 4th quarter. Cullen Capital Management LLC now owns 4,774,380 shares of the biopharmaceutical company’s stock worth $126,664,000 after purchasing an additional 545,406 shares during the period. KCM Investment Advisors LLC grew its holdings in shares of Pfizer by 7.7% in the fourth quarter. KCM Investment Advisors LLC now owns 133,821 shares of the biopharmaceutical company’s stock worth $3,550,000 after purchasing an additional 9,594 shares during the last quarter. Resona Asset Management Co. Ltd. purchased a new position in shares of Pfizer in the fourth quarter worth $48,977,000. Pioneer Trust Bank N A OR boosted its position in Pfizer by 30.4% during the 4th quarter. Pioneer Trust Bank N A OR now owns 12,560 shares of the biopharmaceutical company’s stock valued at $333,000 after buying an additional 2,926 shares during the period. Finally, Unison Advisors LLC grew its holdings in Pfizer by 1.4% in the 4th quarter. Unison Advisors LLC now owns 88,978 shares of the biopharmaceutical company’s stock worth $2,361,000 after acquiring an additional 1,266 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of PFE stock opened at $22.99 on Friday. The company’s fifty day moving average price is $25.87 and its 200-day moving average price is $26.76. The stock has a market cap of $130.39 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $22.95 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.